

Vonoprazan + Amoxicillin + Clarithromycin (VOQUEZNA TRIPLE PAK) Criteria for Use October 2025

VA Pharmacy Benefits Management Services and National Formulary Committee

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE

Exclusion Criteria

EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

If the answer to ANY item below is met, then the patient should NOT receive VOQUEZNA TRIPLE PAK.

- Pregnancy
- Need for concomitant rilpivirine administration
- Serious drug-drug interactions that cannot be managed (e.g., concomitant colchicine if renal or hepatic impairment, pimozide, lurasidone, lovastatin, simvastatin, strong CYP3A inducers)
- Known prolongation of QT interval or ongoing proarrhythmic condition (e.g. uncorrected hypokalemia or hypomagnesemia, significant bradycardia, concomitant Class IA or III antiarrhythmics)

Inclusion Criteria

All of the following criteria must be met.

- Documented H.pylori by laboratory test or pathology
- Documented susceptibility to clarithromycin ^1
- At least one prior course of first-line regimen: bismuth quadruple or vonoprazan dual therapy unless not tolerated or contraindicated
- At least one course of salvage therapy with rifabutin triple therapy unless not tolerated or contraindicated

¹ If clarithromycin susceptibility cannot be documented by culture-based or molecular methods, exceptions to this criterion may be considered on a case-by-case basis with the guidance of a subject matter expert.

Original: Sep 2024.

Revised: Oct 2025. Ian Pace, PharmD, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services (12PBM)

Contact: Francine Goodman, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services (12PBM)
